Community post

John Rex, MD (Chief Medical Officer for Wellcome Trust) has written a blog post about a new paper published by Ursula Theuretzbacher and colleagues on the global pre-clinical pipeline for antibacterials. It shows that as of May 2019, 33/407 preclinical projects were focused on phages or phage-derived therapeutics. Rex mentions that non-traditional antibacterials (like phages) will face substantial hurdles, and describes in a new paper how non-traditional antibacterial development programs should be designed.